Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Ningying Wu, PhD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Camille N. Abboud, MD

Blood (2017) 130 (Supplement 1): 3204.

https://doi.org/10.1182/blood.V130.Suppl_1.3204.3204

Published: 2017

Journal Articles

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ramzi Abboud, MD BS, Michael Slade, MDMS, Kathryn Trinkaus, PhD, Camille N. Abboud, MD, John F DiPersio, MD PhD, Todd A. Fehniger, MDPhD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 3213.

https://doi.org/10.1182/blood.V130.Suppl_1.3213.3213

Published: 2017

Journal Articles

Adherence to Lenalidomide in Older Patients with Multiple Myeloma (MM): A SEER-Medicare Analysis

Tanya Wildes, MD, Mark A. Fiala, BS, Ravi Vij, MDMBA

Blood (2017) 130 (Supplement 1): 3432.

https://doi.org/10.1182/blood.V130.Suppl_1.3432.3432

Published: 2017

Journal Articles

Enhancing Proteasome-Inhibitory Activity and Specificity of Bortezomib By Endocytosis-Mediated Uptake of CD38 Targeted Nanoparticles in Multiple Myeloma

Pilar De La Puente, PhD M.Sc, Abbey Jin, Micah John Luderer, BS, MS, Christopher Egbulefu, Barbara Muz, PhDMSc, Cinzia Federico, PhD, Justin King, Daniel Kohnen, Noha Nabil Salama, PhD, Samuel Achilefu, Ravi Vij, MDMBA, Abdel Kareem Azab, PhD

Blood (2017) 130 (Supplement 1): 1876.

https://doi.org/10.1182/blood.V130.Suppl_1.1876.1876

Published: 2017

Journal Articles

Impact of Active Maintenance Treatment (MT) Compared to No MT on the Quality of Life (QoL) of Patients with Multiple Myeloma (MM) Following First Autologous Stem Cell Transplant (ASCT)

Jason Tay, MD FRCPC, Ravi Vij, MDMBA, Maxim Norkin, MD, Shaji K Kumar, MD, Tamila L Kindwall-Keller, DO, Jenna S Roberts, PhD, Darrell J White, MD, Robert P Wood, BSc, Sophee E Blanthorn-Hazell, MSc, BSc, Adriana C. Rossi, MDMSc, Sujith Dhanasiri, MSc, Faiza Zafar, MPAS, Kim Newhouse, BSc. , BScN, McCurdy R Arleigh, MD MHA, FRCPC

Blood (2017) 130 (Supplement 1): 2150.

https://doi.org/10.1182/blood.V130.Suppl_1.2150.2150

Published: 2017

Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Blood (2017) 130 (Supplement 1): 395.

https://doi.org/10.1182/blood.V130.Suppl_1.395.395

Published: 2017

Journal Articles

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

Michael Slade, MDMS, Ramzi Abboud, MD BS, John F DiPersio, MD PhD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 4575.

https://doi.org/10.1182/blood.V130.Suppl_1.4575.4575

Published: 2017

Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Blood (2017) 130 (Supplement 1): 4533.

https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533

Published: 2017

Journal Articles

Cellular Stressors Contribute to the Expansion of Multiple Hematopoietic Clones of Varying Leukemic Potential

Blood (2017) 130 (Supplement 1): 469.

https://doi.org/10.1182/blood.V130.Suppl_1.469.469

Published: 2017

Journal Articles

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, Camille N. Abboud, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4567.

https://doi.org/10.1182/blood.V130.Suppl_1.4567.4567

Published: 2017

Journal Articles

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Geoffrey L. Uy, MD, Michael P Rettig, PhD, Theresa Fletcher, Peter A Riedell, MD, Keith E. Stockerl-Goldstein, MD, Armin Ghobadi, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, Rizwan Romee, MD, Iskra Pusic, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Peter Westervelt, MDPhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 816.

https://doi.org/10.1182/blood.V130.Suppl_1.816.816

Published: 2017

Journal Articles

Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma

Mark A. Fiala, BS, Sikander Ailawadhi, Ravi Vij, MDMBA, Tanya M. Wildes, MDMSCI

Blood (2017) 130 (Supplement 1): 862.

https://doi.org/10.1182/blood.V130.Suppl_1.862.862

Published: 2017

Journal Articles

A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants

Zhaohui Du, M.S., Niels Weinhold, PhD, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, M.S., Victor Hom, M.S., Sikander Ailawadhi, Ajay K. Nooka, MDMPH, Seema Singhal, MD, Karen Pawlish, Sc.D, M.P.H, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Donglei Hu, M.S., John Graff, PhD, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, John David Carpten, PhD, Graham Casey, PhD, Victoria L. Stevens, PhD, Rick Kittles, PhD, Goodman Phyllis, M.S., Anselm Hennis, MB;BS, MSc., PhD DLSHTM, FRCP, FACP, Eric A. Klein, MD, Barbara Nemesure, Benjamin A. Rybicki, Janet Stanford, John Witte, PhD, Christine B. Ambrosone, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Andrew Olshan, Wei Zheng, MD PhD, Jennifer J. Hu, Regina Ziegler, PhD, M.P.H., Sarah J. Nyante, Elisa Bandera, Sue Ann Ingles, PhD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Michael Tomasson, MD, Mark A. Fiala, BS, Howard Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Loic Le Marchand, MD, PhD, Kenneth C Anderson, MD, Elad Ziv, MD, Brian C.-H. Chiu, PhD, David Conti, PhD, Daniel Stram, PhD, Ravi Vij, MDMBA, Leon Bernal-Mizrachi, MD, Jeffrey A Zonder, MD, Gareth J. Morgan, MD PhD, Carol Ann Huff, MD, Robert Z. Orlowski, MD PhD, Sagar Lonial, MD, Christopher A. Haiman, PhD, Wendy Cozen, DO,MPH

Blood (2017) 130 (Supplement 1): 3058.

https://doi.org/10.1182/blood.V130.Suppl_1.3058.3058

Published: 2017

Journal Articles

A Study to Predict Response to Azacitidine or Lenalidomide/Azacitidine Combination Therapy in MDS and AML Patients Using a Computational Biological Modeling (CBM) Approach

Ravi Vij, MDMBA, Mark A. Fiala, BS, Mathew A. Cherian, MBBS, Neeraj Kumar Singh, B.Tech, Diwyanshu Sahu, M.Sc., Ilu Kumari, M.Sc., Ankitha Narayan, B.E, Poornachandra G, B.Tech, Shireen Vali, PhD, Taher Abbasi, MS, MBA

Blood (2017) 130 (Supplement 1): 2978.

https://doi.org/10.1182/blood.V130.Suppl_1.2978.2978

Published: 2017

Journal Articles

Measuring Cardiopulmonary Complications of Carfilzomib Treatment and Associated Risk Factors Using the SEER-Medicare Database

Bita Fakhri, MDMPH, Mark A. Fiala, BS, Ravi Vij, MDMBA, Tanya M. Wildes, MDMSCI

Blood (2017) 130 (Supplement 1): 3103.

https://doi.org/10.1182/blood.V130.Suppl_1.3103.3103

Published: 2017

Journal Articles

A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MDMSCI, Gunjan L. Shah, MD, Armin Ghobadi, MD, Mark A. Schroeder, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MDMBA

Blood (2017) 130 (Supplement 1): 3108.

https://doi.org/10.1182/blood.V130.Suppl_1.3108.3108

Published: 2017

Journal Articles

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Shivaprasad Manjappa, MD, Mark A. Fiala, BS, Pavan Kumar Bhamidipati, MBBS, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MDMBA, Tanya M. Wildes, MDMSCI

Blood (2017) 130 (Supplement 1): 1860.

https://doi.org/10.1182/blood.V130.Suppl_1.1860.1860

Published: 2017

Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD

Blood (2017) 130 (Supplement 1): 3131.

https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131

Published: 2017

Journal Articles

Targeting CD47 As a Novel Therapeutic Strategy in Multiple Myeloma

Barbara Muz, PhDMSc, Hubert D Kusdono, Justin King, Daniel Kohnen, Mark A. Fiala, BS, Ravi Vij, MDMBA, Ben Capoccia, PhD, Pamela T. Manning, PhD, Noha Nabil Salama, PhD, Abdel Kareem Azab, PhD

Blood (2017) 130 (Supplement 1): 3099.

https://doi.org/10.1182/blood.V130.Suppl_1.3099.3099

Published: 2017

Journal Articles

Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy

Mark A. Schroeder, MD, Mark A. Fiala, BS, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Tanya M. Wildes, MDMSCI, Ravi Vij, MDMBA

Blood (2017) 130 (Supplement 1): 4335.

https://doi.org/10.1182/blood.V130.Suppl_1.4335.4335

Published: 2017

NARROW

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Adherence to Lenalidomide in Older Patients with Multiple Myeloma (MM): A SEER-Medicare Analysis

Enhancing Proteasome-Inhibitory Activity and Specificity of Bortezomib By Endocytosis-Mediated Uptake of CD38 Targeted Nanoparticles in Multiple Myeloma

Impact of Active Maintenance Treatment (MT) Compared to No MT on the Quality of Life (QoL) of Patients with Multiple Myeloma (MM) Following First Autologous Stem Cell Transplant (ASCT)

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Cellular Stressors Contribute to the Expansion of Multiple Hematopoietic Clones of Varying Leukemic Potential

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma

A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants

A Study to Predict Response to Azacitidine or Lenalidomide/Azacitidine Combination Therapy in MDS and AML Patients Using a Computational Biological Modeling (CBM) Approach

Measuring Cardiopulmonary Complications of Carfilzomib Treatment and Associated Risk Factors Using the SEER-Medicare Database

A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Targeting CD47 As a Novel Therapeutic Strategy in Multiple Myeloma

Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only